Bayer manufactures RoundUp, which causes Cancer
Bayer also manufactures Nubeqa, Hyrnuo, Stivarga, Vitrakvi, Xofigo, & Nexavar, expensive drugs that treat, but do not cure, Cancer
BAYERPAC has bribed Conservative Politicians millions
Conservative SCOTUS just ruled in Bayer’s favor
Poison for All
Bayer also manufactures Nubeqa, Hyrnuo, Stivarga, Vitrakvi, Xofigo, & Nexavar, expensive drugs that treat, but do not cure, Cancer
BAYERPAC has bribed Conservative Politicians millions
Conservative SCOTUS just ruled in Bayer’s favor
Poison for All
June 25, 2026 at 4:33 PM
Bayer manufactures RoundUp, which causes Cancer
Bayer also manufactures Nubeqa, Hyrnuo, Stivarga, Vitrakvi, Xofigo, & Nexavar, expensive drugs that treat, but do not cure, Cancer
BAYERPAC has bribed Conservative Politicians millions
Conservative SCOTUS just ruled in Bayer’s favor
Poison for All
Bayer also manufactures Nubeqa, Hyrnuo, Stivarga, Vitrakvi, Xofigo, & Nexavar, expensive drugs that treat, but do not cure, Cancer
BAYERPAC has bribed Conservative Politicians millions
Conservative SCOTUS just ruled in Bayer’s favor
Poison for All
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
https://www.labroots.com/trending/biotech-and-pharma/31041/fda-expands-hyrnuo-her2-mutated-lung-cancer
buff.ly
September 28, 2026 at 12:58 AM
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
The FDA has expanded treatment options for some people with HER2-mutated non-small cell lung cancer (NSCLC), approving Hyrnuo (sevabertinib) as a first-line treatment.
Learn more about the approval: go2.org/blog/fda-mov...
Learn more about the approval: go2.org/blog/fda-mov...
September 11, 2026 at 6:48 PM
The FDA has expanded treatment options for some people with HER2-mutated non-small cell lung cancer (NSCLC), approving Hyrnuo (sevabertinib) as a first-line treatment.
Learn more about the approval: go2.org/blog/fda-mov...
Learn more about the approval: go2.org/blog/fda-mov...
FDA approves HYRNUO® (sevabertinib) for adults with HER2 activating mutations in non-small cell lung cancer post-systemic therapy.
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
December 5, 2025 at 10:10 PM
FDA approves HYRNUO® (sevabertinib) for adults with HER2 activating mutations in non-small cell lung cancer post-systemic therapy.
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
Der Pharmakonzern #Bayer hat von der US-Arzneimittelbehörde #FDA die Zulassung für ein neues #Lungenkrebs -Medikament erhalten. #Hyrnuo
November 20, 2025 at 11:30 AM
Der Pharmakonzern #Bayer hat von der US-Arzneimittelbehörde #FDA die Zulassung für ein neues #Lungenkrebs -Medikament erhalten. #Hyrnuo
US FDA GRANTS PRIORITY REVIEW TO SUPPLEMENTAL NEW DRUG APPLICATION FOR HYRNUO® (SEVABERTINIB) UNDER INVESTIGATION AS A FIRST-LINE TREATMENT OF HER2-MUTATED NON-SMALL CELL LUNG CANCER
May 18, 2026 at 12:45 PM
US FDA GRANTS PRIORITY REVIEW TO SUPPLEMENTAL NEW DRUG APPLICATION FOR HYRNUO® (SEVABERTINIB) UNDER INVESTIGATION AS A FIRST-LINE TREATMENT OF HER2-MUTATED NON-SMALL CELL LUNG CANCER
【HYRNUO（セバベルチニブ）、HER2変異NSCLCで米FDA加速承認】
バイエルの可逆的チロシンキナーゼ阻害薬セバベルチニブ（HYRNUO）が、
HER2変異を有する進行・転移性非小細胞肺がん（NSCLC）を対象に米FDAの迅速承認を取得。
💊 第1／2相SOHO-01試験で**奏効率71％**を報告
⚠️ 下痢・皮疹などの有害事象が高頻度
🔍 臨床的有用性の確証は第3相試験で検証中
HER2変異肺がんという希少サブタイプに対し、初の可逆的TKIとして新たな治療選択肢が登場しました。
#HYRNUO #セバベルチニブ #HER2変異 #非小細胞肺がん #FDA承認 #分子標的薬
バイエルの可逆的チロシンキナーゼ阻害薬セバベルチニブ（HYRNUO）が、
HER2変異を有する進行・転移性非小細胞肺がん（NSCLC）を対象に米FDAの迅速承認を取得。
💊 第1／2相SOHO-01試験で**奏効率71％**を報告
⚠️ 下痢・皮疹などの有害事象が高頻度
🔍 臨床的有用性の確証は第3相試験で検証中
HER2変異肺がんという希少サブタイプに対し、初の可逆的TKIとして新たな治療選択肢が登場しました。
#HYRNUO #セバベルチニブ #HER2変異 #非小細胞肺がん #FDA承認 #分子標的薬
November 24, 2025 at 9:23 PM
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC
https://cancerletter.com/drugs-and-targets/20260918_10b/
https://cancerletter.com/drugs-and-targets/20260918_10b/
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC - The Cancer Letter
FDA has granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advan
cancerletter.com
September 20, 2026 at 1:07 AM
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC
https://cancerletter.com/drugs-and-targets/20260918_10b/
https://cancerletter.com/drugs-and-targets/20260918_10b/
🚨BREAKING: The @fda.gov has granted accelerated approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced/metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations, as detected by an FDA-authorized test #lcsm #oncology
www.onclive.com/view/fda-app...
www.onclive.com/view/fda-app...
September 9, 2026 at 4:00 PM
🚨BREAKING: The @fda.gov has granted accelerated approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced/metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations, as detected by an FDA-authorized test #lcsm #oncology
www.onclive.com/view/fda-app...
www.onclive.com/view/fda-app...
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC
https://cancerletter.com/drugs-and-targets/20260911_10c/
https://cancerletter.com/drugs-and-targets/20260911_10c/
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC - The Cancer Letter
FDA granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced
cancerletter.com
September 16, 2026 at 12:00 PM
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC
https://cancerletter.com/drugs-and-targets/20260911_10c/
https://cancerletter.com/drugs-and-targets/20260911_10c/
Sell $BAYRY (BAYN.DE). Bayer weak: litigation alocation, agriscience cyclicality; Hyrnuo gains priced; EU regs & Mitbestimmung slow tempo. https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-faces-pivotal-test-725-billion-roundup-settlement-missouri-court-2026-09-11/
September 13, 2026 at 6:05 AM
Sell $BAYRY (BAYN.DE). Bayer weak: litigation alocation, agriscience cyclicality; Hyrnuo gains priced; EU regs & Mitbestimmung slow tempo. https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-faces-pivotal-test-725-billion-roundup-settlement-missouri-court-2026-09-11/
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
https://www.labroots.com/trending/biotech-and-pharma/31041/fda-expands-hyrnuo-her2-mutated-lung-cancer
www.labroots.com
September 11, 2026 at 2:23 PM
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
https://www.labroots.com/trending/biotech-and-pharma/31041/fda-expands-hyrnuo-her2-mutated-lung-cancer
www.labroots.com
September 11, 2026 at 2:22 PM
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
https://www.labroots.com/trending/biotech-and-pharma/31041/fda-expands-hyrnuo-her2-mutated-lung-cancer
www.labroots.com
September 11, 2026 at 2:22 PM
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
https://www.labroots.com/trending/biotech-and-pharma/31041/fda-expands-hyrnuo-her2-mutated-lung-cancer
www.labroots.com
September 11, 2026 at 2:22 PM
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
https://www.labroots.com/trending/biotech-and-pharma/31041/fda-expands-hyrnuo-her2-mutated-lung-cancer
www.labroots.com
September 11, 2026 at 2:22 PM
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
https://www.labroots.com/trending/biotech-and-pharma/31041/fda-expands-hyrnuo-her2-mutated-lung-cancer
www.labroots.com
September 11, 2026 at 2:22 PM
FDA expands Bayer’s Hyrnuo approval to first-line treatment for HER2-mutated NSCLC, after the drug showed a 75% response rate in previously untreated patients. buff.ly/lRXt0XI
FDA Expands Indication for Bayer’s Hyrnuo to First-Line HER2-Mutant NSCLC
FDA Expands Indication for Bayer’s Hyrnuo to First-Line HER2-Mutant NSCLC
The accelerated approval was based on results from the Phase I/II SOHO-01 trial showing a 75 percent response rate to first-line Hyrnuo.
ebx.sh
September 10, 2026 at 6:26 PM
FDA Expands Indication for Bayer’s Hyrnuo to First-Line HER2-Mutant NSCLC
The #FDA has granted accelerated approval to #sevabertinib (#Hyrnuo) for adults with locally advanced/metastatic non-squamous NSCLC harboring activating HER2 (#ERBB2) tyrosine kinase domain mutations.
SOHO-01 trial: 75% objective response rate in patients who had not received prior systemic therapy
SOHO-01 trial: 75% objective response rate in patients who had not received prior systemic therapy
September 11, 2026 at 9:00 AM
The #FDA has granted accelerated approval to #sevabertinib (#Hyrnuo) for adults with locally advanced/metastatic non-squamous NSCLC harboring activating HER2 (#ERBB2) tyrosine kinase domain mutations.
SOHO-01 trial: 75% objective response rate in patients who had not received prior systemic therapy
SOHO-01 trial: 75% objective response rate in patients who had not received prior systemic therapy
#Bayer has won #FDAapproval for #oralHER2inhibitor #Hyrnuo as a #firstlinetreatment for advanced HER2-mutant non-small cell lung cancer (#NSCLC), just a year after it was cleared as a second-line option.
pharmaphorum.com/news/bayer-m...
pharmaphorum.com/news/bayer-m...
Bayer moves Hyrnuo into frontline lung cancer treatment
Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.
pharmaphorum.com
September 10, 2026 at 11:30 AM
#Bayer has won #FDAapproval for #oralHER2inhibitor #Hyrnuo as a #firstlinetreatment for advanced HER2-mutant non-small cell lung cancer (#NSCLC), just a year after it was cleared as a second-line option.
pharmaphorum.com/news/bayer-m...
pharmaphorum.com/news/bayer-m...
Thur news: Novartis shareholder calls for board overhaul following costly deal setbacks. Novo Nordisk's Wegovy pioneers MASH treatment in China. August biopharma layoffs down 90% YoY. FDA clears Bayer’s Hyrnuo in first-line lung cancer. —https://bit.ly/3JeBlY5
September 10, 2026 at 3:43 PM
Thur news: Novartis shareholder calls for board overhaul following costly deal setbacks. Novo Nordisk's Wegovy pioneers MASH treatment in China. August biopharma layoffs down 90% YoY. FDA clears Bayer’s Hyrnuo in first-line lung cancer. —https://bit.ly/3JeBlY5
FDA News🇺🇸 Sevabertinib Approved in Locally Advanced #NSCLC #LungCancer
On September 9, 2026, the FDA granted accelerated approval to sevabertinib (Hyrnuo) for adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 (ERBB2) TKD activating mutations
www.fda.gov/drugs/resour...
On September 9, 2026, the FDA granted accelerated approval to sevabertinib (Hyrnuo) for adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 (ERBB2) TKD activating mutations
www.fda.gov/drugs/resour...
September 9, 2026 at 6:04 PM
FDA News🇺🇸 Sevabertinib Approved in Locally Advanced #NSCLC #LungCancer
On September 9, 2026, the FDA granted accelerated approval to sevabertinib (Hyrnuo) for adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 (ERBB2) TKD activating mutations
www.fda.gov/drugs/resour...
On September 9, 2026, the FDA granted accelerated approval to sevabertinib (Hyrnuo) for adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 (ERBB2) TKD activating mutations
www.fda.gov/drugs/resour...
バイエルのセバベルチニブ（商品名ヒアニュオ）。
対象は、HER2変異陽性で、切除できない進行・再発の非小細胞肺がんです。
一次治療から使えます。未治療の第1/2相試験では、腫瘍が縮小した人が約75％でした。
下痢や発疹なども報告されています。
HER2変異陽性肺がん治療薬セバベルチニブが日本で承認
stellanews.life/technology/1...
#セバベルチニブ日本承認
対象は、HER2変異陽性で、切除できない進行・再発の非小細胞肺がんです。
一次治療から使えます。未治療の第1/2相試験では、腫瘍が縮小した人が約75％でした。
下痢や発疹なども報告されています。
HER2変異陽性肺がん治療薬セバベルチニブが日本で承認
stellanews.life/technology/1...
#セバベルチニブ日本承認
HER2変異陽性非小細胞肺がん治療薬セバベルチニブ（商品名ヒアニュオ）が日本で承認──バイエル薬品が製造販売承認取得を発表
Bayerは2026年8月24日、HER2遺伝子変異陽性の非小細胞肺がん（NSCLC）を対象に、セバベルチニブ（Hyrnuo）が日本の厚生労働省から承認されたと発表した。第1/2相SOHO-01試験の主要結果と安全性、臨床的位置づけを整理する。
stellanews.life
August 27, 2026 at 10:37 PM
バイエルのセバベルチニブ（商品名ヒアニュオ）。
対象は、HER2変異陽性で、切除できない進行・再発の非小細胞肺がんです。
一次治療から使えます。未治療の第1/2相試験では、腫瘍が縮小した人が約75％でした。
下痢や発疹なども報告されています。
HER2変異陽性肺がん治療薬セバベルチニブが日本で承認
stellanews.life/technology/1...
#セバベルチニブ日本承認
対象は、HER2変異陽性で、切除できない進行・再発の非小細胞肺がんです。
一次治療から使えます。未治療の第1/2相試験では、腫瘍が縮小した人が約75％でした。
下痢や発疹なども報告されています。
HER2変異陽性肺がん治療薬セバベルチニブが日本で承認
stellanews.life/technology/1...
#セバベルチニブ日本承認
Bayer’s Oncology Pipeline Gains Traction in Japan, Yet the Glyphosate Clock Keeps Ticking
The pharma division of Bayer has quietly become the company’s most reliable source of good news. The latest development arrived this week when Japanese regulators granted marketing approval for Sevabertinib,…
The pharma division of Bayer has quietly become the company’s most reliable source of good news. The latest development arrived this week when Japanese regulators granted marketing approval for Sevabertinib,…
Bayer’s Oncology Pipeline Gains Traction in Japan, Yet the Glyphosate Clock Keeps Ticking
The pharma division of Bayer has quietly become the company’s most reliable source of good news. The latest development arrived this week when Japanese regulators granted marketing approval for Sevabertinib, the company’s targeted therapy for HER2-mutant non-small cell lung cancer (NSCLC). Sold under the brand name Hyrnuo in Japan, the drug has secured a clearance [...] The post Bayer’s Oncology Pipeline Gains Traction in Japan, Yet the Glyphosate Clock Keeps Ticking appeared first on NewsCase .
news-area.com
August 26, 2026 at 3:58 PM
Bayer’s Oncology Pipeline Gains Traction in Japan, Yet the Glyphosate Clock Keeps Ticking
The pharma division of Bayer has quietly become the company’s most reliable source of good news. The latest development arrived this week when Japanese regulators granted marketing approval for Sevabertinib,…
The pharma division of Bayer has quietly become the company’s most reliable source of good news. The latest development arrived this week when Japanese regulators granted marketing approval for Sevabertinib,…